EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria

Marisa L Winkler iD, Paul R Rhomberg, Kelley A Fedler, Michael D Huband, Maura Karr, John H Kimbrough iD, Mariana Castanheira

Journal of Clinical Microbiology · 2025

DOI: 10.1128/jcm.01207-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Marisa L Winkler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Aspergillus fumigatus, Voriconazole, Triazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aspergillus fumigatus is a common cause of pulmonary and invasive mold infections among immunocompromised hosts. Mortality in immunocompromised hosts with invasive Aspergillus infections (IAI) has been reported to be as high as 80%. Therefore, appropriate therapy is essential in treating IAI. Both isavuconazole and voriconazole are first-line agents in treatment guidelines for IAI, but isavuconazole has favorable properties, often leading it to be preferred over voriconazole, given the lengthy duration of treatment. It is difficult to perform mold antifungal susceptibility testing, which often requires a reference lab and several weeks to determine results. Therefore, use of surrogate markers can be helpful to infer susceptibility when testing is not possible or delayed. We performed isavuconazole and voriconazole broth microdilution susceptibility testing by the Clinical and Laboratory Standards Institute (CLSI) method on a collection of 976 non-duplicate A. fumigatus isolates from a global surveillance program between 2017 and 2022. We found that voriconazole and isavuconazole have a very high essential agreement within two doubling dilutions at 99.9% and a categorical agreement of 92.7% with no very major errors, one major error (0.11%), and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAspergillus fumigatusVoriconazoleTriazolesNitrilesPyridinesDrug Resistance, FungalMicrobial Sensitivity TestsHumansAspergillosisFungal Proteins

Stichwörter der Autor:innen

Aspergillus fumigatusisavuconazolesurrogate markersusceptibility testing

Substanzen

isavuconazoleAntifungal AgentsVoriconazoleTriazolesNitrilesPyridinesFungal Proteins

Autor:innen und Institutionen

  • Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.

ORCID-Profile: Marisa L Winkler, John H Kimbrough

Zitieren

APA

Winkler, M. L., Rhomberg, P. R., Fedler, K. A., Huband, M. D., Karr, M., Kimbrough, J. H., & Castanheira, M. (2025). Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01207-24

Vancouver

Winkler ML, Rhomberg PR, Fedler KA, Huband MD, Karr M, Kimbrough JH, et al. Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.01207-24

BibTeX
@article{Winkler2025,
  author = {Winkler, Marisa L and Rhomberg, Paul R and Fedler, Kelley A and Huband, Michael D and Karr, Maura and Kimbrough, John H and Castanheira, Mariana},
  title = {Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  doi = {10.1128/jcm.01207-24}
}
Kostenlos starten →